Dallas-based Canyon Capital Advisors increased its stake in MasterBrand by 734,854 shares in Q3 2025, signaling potential confidence despite the company's recent challenges in the homebuilding supply sector.

Coliseum Capital Management invested $52.6 million in MasterBrand during Q3, increasing its stake to 7.6 million shares. Despite a 35% stock decline over the past year, the fund sees potential value in the cabinetry company amid a soft housing market.

Law firm Kahn Swick & Foti is investigating the proposed sale of American Woodmark to MasterBrand, questioning whether the transaction adequately values the company.

Law firm Monteverde & Associates is investigating the proposed sale of American Woodmark Corporation to MasterBrand, where each American Woodmark share will be exchanged for 5.150 shares of MasterBrand common stock.

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. Trupanion, Inc. (NASDAQ: TRUP) shares surged 16.4% to $23.96 in pre-market trading after California and New York approved the company's requested rate increases. Beneficient (NASDAQ: BENF) gained 12.1% to $4.37 in pre-market trading after dropping around 10% on Thursday. IonQ, Inc. (NYSE: IONQ) shares surged 8.9% to $10.27 in pre-market trading after the company lifted its booking expectations for the year by 25% to ...

Loop Capitals Markets analysts Garik Shmois and Jeffrey Stevenson upgraded MasterBrand Inc (NYSE: MBC) to Buy from Hold at an increased price target of $13 from $9.  The analysts are upbeat about the company on strong Q1 beat and increased 2023 guidance.  Yesterday, the company reported Q1 2023 revenues of $676.7 million, beating the consensus of $629 ...Full story available on Benzinga.com

Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday. Harbor Custom Development, Inc. (NASDAQ: HCDI) gained 172% to $12.99 after the company announced a buyer waived all contingencies on a $14,250,000 sale of townhomes. CTI BioPharma Corp. (NASDAQ: CTIC) jumped 84.9% to $8.91 after Swedish Orphan Biovitrum AB announced plans to acquire CTI BioPharma in a transaction worth $1.7 billion. Microvast Holdings, Inc. (NASDAQ: MVST) rose 42% to $1.8633 after the company reported better-than-expected Q1 sales results. Chanson International Holding (NASDAQ: CHSN) gained 41% to $2.22 after the company announced fiscal year 2022 financial results. LivePerson, Inc. (NASDAQ: LPSN) jumped 33% to $5.79 after the company reported better-than-expected sales results. Compass, Inc. (NYSE: COMP) rose 31% to $3.6850 after the company reported better-than-expected Q1 financial results and issued guidance. Xometry, Inc. (NASDAQ: XMTR) jumped 30% to $17.40 after the company reported better-than-expected Q1 adjusted EPS and sales results. Upstart Holdings, Inc. (NASDAQ: UPST) rose 29.8% to $18.30 after the company reported better-than-expected Q1 EPS and issued strong Q2 guidance. Cano Health, Inc. (NYSE: CANO) gained 29% to $1.3550 after the company reported better-than-expected Q1 EPS and sales results. Benson Hill, Inc. (NASDAQ: BHIL) rose 28.6% to $1.5821 after the company reported a year-over-year increase in Q1 EPS results and reported better-than-expected Q1 sales results. Angi Inc. (NASDAQ: ANGI) gained 27.6% to $3.19 after the company reported better-than-expected Q1 EPS and sales results. GrowGeneration Corp. (NASDAQ: GRWG) rose 27.5% to $4.72 after the company reported better-than-expected Q1 EPS and sales results. Vyant Bio, Inc. (NASDAQ: VYNT) gained 27% to $0.3690. Upstart Holdings, Inc. (NASDAQ: UPST) surged 26.6% to $17.85 after the company reported better-than-expected Q1 EPS and issued strong Q2 guidance. Open Lending Corporation (NASDAQ: LPRO) gained 24% to $9.39 after the company reported better-than-expected Q1 EPS results. LegalZoom.com, Inc. (NASDAQ: LZ) gained 23.5% to $10.29 after the company reported better-than-expected Q1 adjusted EPS and sales results. Additionally, the company issued Q2 revenue guidance above analyst estimates. Versus Systems Inc. (NASDAQ: VS) climbed 23% to $0.7792 after the company announced ...

U.S. stocks traded mixed, with the Dow Jones dropping around 70 points on Wednesday. Here are some big stocks recording gains in today’s session. CTI BioPharma Corp. (NASDAQ: CTIC) climbed 84.9% to $8.91 after Swedish Orphan Biovitrum AB announced plans to acquire CTI BioPharma in a transaction worth $1.7 billion. Microvast Holdings, Inc. (NASDAQ: MVST) gained 42% to $1.8633 after the company reported better-than-expected Q1 sales results. LivePerson, Inc. (NASDAQ: LPSN) jumped 33% to $5.79 after the company reported better-than-expected sales results. Compass, Inc. (NYSE: COMP) surged 31% to $3.6850 after the company reported better-than-expected Q1 financial results and issued guidance. Xometry, Inc. (NASDAQ: XMTR) rose 30% to $17.40 after the company reported better-than-expected Q1 adjusted EPS and sales results. Upstart Holdings, Inc. (NASDAQ: UPST) gained 29.8% to $18.30 after the company reported better-than-expected Q1 EPS and issued strong Q2 guidance. Angi Inc. (NASDAQ: ANGI) climbed 27.6% to $3.19 after the company reported better-than-expected Q1 EPS and sales results. GrowGeneration Corp. (NASDAQ: GRWG) gained 27.5% to $4.72 after the company reported better-than-expected ...

Upgrades For Tabula Rasa HealthCare Inc (NASDAQ:TRHC), SVB Leerink upgraded the previous rating of Market Perform to Outperform. Tabula Rasa HealthCare earned $0.02 in the first quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Tabula Rasa HealthCare shows a 52-week-high of $6.69 and a 52-week-low of $2.09. Moreover, at the end of the last trading period, the closing price was at $5.52. According to Maxim Group, the prior rating for Paltalk Inc (NASDAQ:PALT) was changed from Hold to Buy. Paltalk earned $0.08 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Paltalk shows a 52-week-high of $4.60 and a 52-week-low of $1.28. Moreover, at the end of the last trading period, the closing price was at $2.26. According to Northland Capital Markets, the prior rating for Vitesse Energy Inc (NYSE:VTS) was changed from Market Perform to Outperform. In the first quarter, Vitesse Energy showed an EPS of $0.53, compared to $0.02 from the year-ago quarter. The stock has a 52-week-high of $20.99 and a 52-week-low of $13.90. At the end of the last trading period, Vitesse Energy closed at $18.71. For Jack In The Box Inc (NASDAQ:JACK), OTR Global upgraded the previous rating of Mixed to Positive. In the first quarter, Jack In The Box showed an EPS of $2.01, compared to $1.97 from the year-ago quarter. The stock has a 52-week-high of $94.93 and a 52-week-low of $54.86. At the end of the last trading period, Jack In The Box closed at $92.61. Craig-Hallum upgraded the previous rating for GrowGeneration Corp (NASDAQ:GRWG) from Hold to Buy. GrowGeneration earned $0.10 in the first quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $8.62 and a 52-week-low of $2.77. At the end of the last trading period, GrowGeneration closed at $3.70. For Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), Oppenheimer upgraded the previous rating of Perform to Outperform. Corbus Pharmaceuticals earned $4.24 in the first quarter, compared to $2.40 in the year-ago quarter. The stock has a 52-week-high of $13.17 and a 52-week-low of $2.11. At the end of the last trading period, Corbus Pharmaceuticals closed at $8.87. For Albemarle Corp (NYSE:ALB), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. In the first quarter, Albemarle showed an EPS of $10.32, compared to $2.38 from the year-ago quarter. At the moment, the stock has a 52-week-high of $334.20 and a 52-week-low of $171.82. Albemarle closed at $195.17 at the end of the last trading period. B of A Securities upgraded the previous rating for Celsius Holdings Inc (NASDAQ:CELH) from Neutral to Buy. Celsius Holdings earned $0.40 in the first quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Celsius Holdings shows a 52-week-high of $122.24 and a 52-week-low of $38.38. Moreover, at the end of the last trading period, the closing price was at $107.12. According to B of A Securities, the prior rating for InterDigital Inc (NASDAQ:IDCC) was changed from Underperform to Buy. InterDigital earned $4.21 in the first quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $81.95 and a 52-week-low of $40.24. At the end of the last trading period, InterDigital closed at $80.00. According to Craig-Hallum, the prior rating for Quotient Technology Inc (NYSE:QUOT) was changed from Hold to Buy. For the first quarter, Quotient Technology had an EPS of $0.18, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $4.56 and a 52-week-low of $1.68. Quotient Technology closed at $2.90 at the end of the last trading period. Craig-Hallum upgraded the previous rating for Exact Sciences Corp (NASDAQ:EXAS) from Hold to Buy. For the first quarter, Exact Sciences had an EPS of $0.42, compared to year-ago quarter EPS of $1.04. The stock has a 52-week-high of $72.19 and a 52-week-low of $29.29. At the end of the last trading period, Exact Sciences closed at $71.00. For MasterBrand Inc (NYSE:MBC), Loop Capital upgraded the previous rating of Hold to Buy. For the first quarter, MasterBrand had an EPS of $0.28, compared to year-ago quarter EPS of $0.40. The current stock performance of MasterBrand shows a 52-week-high of $10.21 and a 52-week-low of $7.08. Moreover, at the end of the last trading period, the closing price was at $8.64. For Y-mAbs Therapeutics Inc (NASDAQ:YMAB), Wedbush upgraded the previous rating of Neutral to Outperform. For the first quarter, Y-mAbs Therapeutics had an EPS of $0.15, compared to year-ago quarter EPS of $0.64. At the moment, the stock has a 52-week-high of $20.31 and a 52-week-low of $2.70. Y-mAbs Therapeutics closed at $9.23 at the end of the last trading period. Jefferies upgraded the previous rating for Nektar Therapeutics (NASDAQ:NKTR) from Underperform to Hold. For the first quarter, Nektar Therapeutics had an EPS of $0.25, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $5.17 and a 52-week-low of $0.60. Nektar Therapeutics closed at $0.77 at the end of the last trading period. Itau BBA upgraded the previous rating for Vtex (NYSE:VTEX) ...Full story available on Benzinga.com

Six students completed due diligence on a stock of their choice for the Maize and Blue Stock Pitch Competition at the University of Michigan on Friday.  The students were given feedback during the process by three judges: Corey Tobin, investment management analyst at William Blair; Jordan Hymowitz, managing principal at Philadelphia Financial Management; and Matthew Finn, CFA, senior portfolio manager at Thrivent Financial.  Interestingly, five of the issues were pitched from a bullish perspective and only one was pitched as a potential short.  The three presentations that did not finish in the money were excellent. All presenters were more than well-prepared and were poised during their presentations. In addition, all of the presenters handled the grilling during the Q&A portion with ease. Stay tuned, as some of the participants will be making their stock pitches to the PreMarket Prep audience in the coming weeks. Here's what Benzinga witnessed during the competition among undergraduate and MBA students, held at the Tozzi Electronic Business and Finance Center at the Ross School of Business at the University of Michigan.  The competition awarded $5,000 for first place; $2,000 for second and $1,000 for third. Related Link: EXCLUSIVE: Ryan Detrick Remains Cautiously Optimistic, But Says Watch The XLF Sajiv Shah, Bullish Gray Television: Sajiv Shah made a compelling bullish presentation for Gray ...

2022 was another fantastic year for dividend growth, with my income increasing by over 13%. Find out every sale made in the year and the replacement purchases.

I review my current holdings and sectors in the portfolio and how it has changed over the years. See my income projections for 2023 and potential pitfalls.